Trevena Appoints Julie McHugh And Barbara Yanni As Board Members

(RTTNews) - Trevena, Inc. (TRVN), a clinical stage biopharmaceutical company, Tuesday announced that it has appointed Julie McHugh, former president of Centocor and chief operating officer at Endo Health Solutions, and Barbara Yanni, former chief licensing officer at Merck & Co., to its Board of Directors.

The two directors replace Terrance McGuire and David Solomon, who are stepping down from the Board following the company's recent initial public offering.

McHugh has over 28 years of experience in the drug development industry. From 2004 to 2006 she was president of Centocor, Inc., a J&J subsidiary (JNJ), where she oversaw the development and launch of Remicade (infliximab). From 2006 to 2008, she served as company group chairman for Johnson & Johnson's worldwide virology business unit.

Most recently she served as chief operating officer at Endo Health Solutions Inc. from 2010 to 2013. She has also served as chief executive officer of Nora Therapeutics, Inc., a private biotech company.

The company further said that Yanni had a 28-year career at Merck & Co., Inc. (MRK), where she was vice president and chief licensing officer before her retirement in March 2014.

McHugh said, "Trevena has rapidly translated its novel biased ligand platform into a portfolio of differentiated candidates, each of which represents a significant commercial opportunity and addresses an unmet need in the marketplace. It is an exciting time in the Company's evolution, and I look forward to working with the Board to advance the Company's efforts to deliver the next generation of GPCR targeted medicines."